spacer
home > ebr > summer 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

“It is important that rare disease businesses bring treatments to market as early as possible to give patients the best chance,” say Sobi’s Hege Hellström and Neil Dugdale in our summer 2017 industry Q&A. This captures the essence of therapy research and development for these often life-limiting illnesses affecting an estimated 70,000 patient groups. Access to the therapy, not just producing and commercialising it, should be a priority.

‘Salami-slicing’ of mass market, non-rare diseases to create artificial orphan indications is increasingly blurring lines between big pharma and specialised focus, according to The Weinberg Group’s Matthew Weinberg and Emily Krulewitz. Its driver is seemingly pharmacogenomics and the ability to stratify patients inside a group based on their genome and consequent response to particular therapies, switching them to personalised medicines.

Hermann Mascher at pharm-analyt Labor reminds us of the transformational potential these patient-specific therapeutics offer, and that particular biochemical pathways’ missing or defective components can be both the biomarker to identify a disease’s subset and the therapy to restore that deletion. If these could be characterised by bioanalytical methodologies serving a range of conditions, more synthetic forms of these endogenous small molecules may come on stream in development as therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Clinical Services Welcomes Marc Rees to its International Clinical Sales Team

Leading outsourcing services provider PCI Clinical Services has announced the appointment of Marc Rees in the role of Business Development Manager responsible for UK and Ireland.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

LogiMed 2017

18-19 October 2017, Hyperion Hotel, Hamburg

Taking place 18-19th October in Hamburg, LogiMed is Europe’s only dedicated medical device supply chain event bringing together over 150 Medical Device Supply Chain Professionals to network with. With a greater focus on customer collaboration and digital transformation this year’s LogiMed delivers real insights on inventory visibility, supply chain planning, global logistics and digitalization.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement